New Molecular Entity (NME)

A New Molecular Entity (NME) is FDA’s classification for a new drug application whose active ingredient — specifically its active moiety, the part of the molecule responsible for the drug’s therapeutic action — has not been previously approved by FDA in any other application. It is the agency’s headline measure of genuine pharmaceutical innovation, distinguishing a truly novel active ingredient from a new formulation, new dosage form, new fixed-dose combination, or new indication for a drug FDA has already approved. NME applies to both small-molecule chemical drugs and biologics; the small-molecule subset has its own narrower classification, New Chemical Entity (NCE), which carries a distinct regulatory-exclusivity consequence NME alone does not.

The active-moiety test

FDA’s NDA Classification Codes framework defines an NME as an active ingredient that contains no active moiety previously approved by the agency in any application — not a comparison of the whole drug product, but of the moiety, the specific chemical structure responsible for the drug’s activity, stripped of any ester, salt, or other non-covalent derivative attached to it. That distinction matters in practice: a manufacturer that reformulates an already-approved active moiety into a new salt form, a new delivery mechanism, or a new combination product is not filing an NME application, even though the resulting product is in every other sense “new.” The active-moiety test is what keeps the NME count a measure of genuinely novel chemistry or biology, rather than a measure of new SKUs.

NME vs. NCE vs. NBE

NME is the umbrella classification; it splits into two narrower categories depending on what kind of molecule is involved:

• New Chemical Entity (NCE) — the small-molecule subset of NME: a synthesized chemical drug substance with no active moiety FDA has previously approved. See CASRAI’s dedicated New Chemical Entity (NCE) entry for why this narrower category exists as its own regulatory concept.
• New Biological Entity (NBE) — the biologic subset of NME: a novel therapeutic protein, monoclonal antibody, gene therapy, cell therapy, or other biologic product with no previously approved active moiety, reviewed under the Public Health Service Act via a Biologics License Application (BLA) rather than an NDA.

Every NCE and every NBE is an NME; not every NME is an NCE, because NME also captures novel biologics. This hierarchy is the single most common source of confusion in casual usage — “NME” and “NCE” are frequently used interchangeably in industry writing even though they describe different-sized categories.

Why the classification matters

Two separate consequences follow from an application being classified as an NME, and they are easy to conflate:

• FDA’s own tracking and reporting. CDER’s annual Novel Drug Approvals report uses the NME/new biologic count as its headline figure for how much genuinely new pharmaceutical innovation reached the U.S. market that year — 2018’s count of 59 was, at the time, the highest ever recorded, edging out the previous 1996 record of 55 (itself inflated by clearance of a PDUFA-era application backlog). Small molecules have historically made up roughly two-thirds of NMEs in a given year, with most of the remainder being biologics.
• Regulatory exclusivity — but only for the NCE subset. Under 21 CFR 314.108, a drug meeting the New Chemical Entity definition (no active moiety previously approved in any application submitted under FDCA section 505(b)) can receive five years of marketing exclusivity, during which FDA is generally barred from accepting an ANDA or 505(b)(2) application relying on that same active moiety. This exclusivity runs independently of any patent protection the sponsor holds, and applies to the NCE subset specifically — NME status alone, for a biologic, does not trigger it; biologics have their own exclusivity framework under the Public Health Service Act.

Worked example

A sponsor completes Phase 1–3 trials of a novel small-molecule compound under an IND, and no active moiety in the compound has ever appeared in a previously approved FDA application. The resulting NDA is classified as an NME — and, because it is also a small molecule meeting the 314.108 definition, as an NCE, triggering five-year exclusivity on approval.

Counter-example

A manufacturer files an NDA for an extended-release formulation of a drug whose active moiety FDA approved a decade earlier under a different brand. The new formulation may still earn three-year formulation-specific exclusivity if it required new clinical studies, but it is not an NME — the active moiety itself is not new, only the delivery mechanism is.

Related CASRAI content

See New Chemical Entity (NCE) for the small-molecule subset and its exclusivity mechanics in more depth, 21 CFR Part 314 for the NDA/ANDA framework this classification sits inside, and Chemistry, Manufacturing, and Controls (CMC) for the technical dossier section that documents the active ingredient FDA is evaluating for novelty.

Frequently Asked Questions

Is a new biologic an NME?

Yes. NME covers any drug application — small-molecule or biologic — whose active moiety has not been previously approved by FDA. A novel biologic is sometimes called a “new biologic” or New Biological Entity (NBE) in FDA’s own reporting, but it is counted within the broader NME/new biologic approval totals.

Does NME status automatically mean five years of exclusivity?

No. Five-year New Chemical Entity exclusivity under 21 CFR 314.108 applies specifically to the small-molecule NCE subset of NME. A novel biologic (an NBE) is an NME but is not an NCE, and its exclusivity is instead governed by the Public Health Service Act’s biologics framework, not 314.108.